Posted on

BEST PSYCHEDELICS SHOPS IN USA

 BEST PSYCHEDELICS SHOPS IN USA

10. Seelos Therapeutics, Inc

Seelos Therapeutics, Inc. (NASDAQ: SEEL) is placed tenth on our list of 10 best psychedelic companies to watch. The stock has offered investors returns exceeding 171% over the course of the past twelve months. The company is a clinical biopharmaceutical entity focusing on the development of novel therapeutics and technologies for treatment of diseases related to the central nervous system. The company is part of the first exchange traded fund on psychedelics. One of the lead drugs of the firm, SLS-002, for treating depression, is psychedelic-related.

On June 28, Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it had been included in the Russell 2000 and Russell 3000 indexes. Raj Mehra, the CEO of the firm, announced the inclusion and said it would increase the exposure in the investment community.

At the end of the first quarter of 2021, 11 hedge funds in the database of Insider Monkey held stakes worth $47 million in Seelos Therapeutics, Inc. (NASDAQ: SEEL), up from 4 the preceding quarter worth $1.3 million.

Just like COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTC: FTRPF), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), and Cybin Inc. (OTC: CLXPF), Seelos Therapeutics, Inc. (NASDAQ: SEEL) is one of the best psychedelic and healthcare companies to watch.

9. HAVN Life Sciences Inc. (OTC: HAVLF)

HAVN Life Sciences Inc. (OTC: HAVLF) is a biotechnology company based in Canada. It is ranked ninth on our list of 10 best psychedelic companies to watch. The company markets itself as the future of psychedelic medicine. Some of the products it offers include Cordyceps Perform, made up of cordyceps mushrooms to help lung and kidney function and fight against free radical cell damage, and Mind Mushroom, a four-mushroom offering that helps with Immunity and energy balance.

On May 17, HAVN Life Sciences Inc. (OTC: HAVLF) announced that it had entered into a deal with another biotech firm to purchase intellectual property related to LSD-linked drugs that may help with cluster headaches.

HAVN Life Sciences Inc. (OTC: HAVLF) signed the agreement for $1 million plus more than 10 million common shares subject to certain conditions. Tim Moore, the CEO of Havn, said on the occasion that the agreement marked a strategic shift for the firm.

Just like COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTC: FTRPF), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), and Cybin Inc. (OTC: CLXPF), HAVN Life Sciences Inc. (OTC: HAVLF) is one of the best psychedelic and healthcare companies to watch.

8. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a biotechnology company that focuses on psychedelic medicine to treat addictions and mental illnesses. Some of the psychedelic substances it is using to develop drugs include Psilocybin, LSD, MDMA, DMT, and others. It is placed eighth on our list of 10 best psychedelic companies to watch. The company’s shares have offered investors returns exceeding 1,000% over the course of the past year. The company is based in New York.

On June 28, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was included on the Russell 3000 Index. The share price of the firm jumped close to 5 % upon the inclusion. The index tracks the performance of the 3,000 largest companies in the United States.

On May 24, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) entered into an agreement with Nextage Therapeutics for collaboration on development of psychedelic drugs. Nextage granted the biotech firm limited rights to intellectual property on these drugs as part of the deal.

Just like COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTC: FTRPF), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), and Cybin Inc. (OTC: CLXPF), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is one of the best psychedelic and healthcare companies to watch.

7. Numinus Wellness Inc. (OTC: LKYSF)

Numinus Wellness Inc. (OTC: LKYSF) is a company that markets psychedelic psychotherapy for mental health problems. It is ranked seventh on our list of 10 best psychedelic companies to watch. The stock has returned more than 184% to investors in the past twelve months. The company has two separate divisions for psychedelics, one dedicated to laboratory services and the other to supportive therapies. It is based in Canada and has a market capitalization of over $150 million. It posted more than 650,000 in annual revenue last year.

In earnings results for the second fiscal quarter, posted on April 30, Numinus Wellness Inc. (OTC: LKYSF) reported a revenue of C$0.23 million, down close to 11% compared to the revenue over the same period in the previous fiscal year.

In the first fiscal quarter, the revenue for Numinus Wellness Inc. (OTC: LKYSF) had also been C$0.23 million. However, in the first fiscal quarter, this represented an increase of more than 76% compared to the revenue in the first fiscal quarter of the previous year.

Just like COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTC: FTRPF), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), and Cybin Inc. (OTC: CLXPF), Numinus Wellness Inc. (OTC: LKYSF) is one of the best psychedelic and healthcare companies to watch.

6. Atai Life Sciences N.V. (NASDAQ: ATAI)

Atai Life Sciences N.V. (NASDAQ: ATAI) is a biopharmaceutical firm concentrating on the development of drugs to treat different kinds of mental health disorders. These drug candidates, some which use psychedelic substances, include PCN-101 and RL-007, among others. The former is a treatment for resistant depression and the latter is for treatment of cognitive impairment because of schizophrenia. The firm is placed sixth on our list of 10 best psychedelic companies to watch.

Atai Life Sciences N.V. (NASDAQ: ATAI) is backed by famous investor Peter Thiel, who has invested in several incredibly successful technology companies over the years. The company went public earlier this month and finished the first day of trading valued at over $2 billion.

At the end of the first quarter of 2021, 3 hedge funds in the database of Insider Monkey held stakes worth $782,000 in Atai Life Sciences N.V. (NASDAQ: ATAI), up from 1 in the previous quarter worth $118,000.

Just like COMPASS Pathways plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTC: FTRPF), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), GlaxoSmithKline plc (NYSE: GSK), and Cybin Inc. (OTC: CLXPF), Atai Life Sciences N.V. (NASDAQ: ATAI) is one of the best psychedelic and healthcare companies to watch.

Leave a Reply

Your email address will not be published.